Discounted Cash Flow
Halozyme Therapeutics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $146.7m | $-103.0m | $-53.5m | -70.2% | $-0.81 |
| 2017 | $316.6m (115.8%) | $63.0m (161.1%) | $132.7m (348.0%) | 19.9% (128.3%) | $0.46 (156.8%) |
| 2018 | $151.9m (-52.0%) | $-80.3m (-227.6%) | $-54.2m (-140.8%) | -52.9% (-366.0%) | $-0.56 (-221.7%) |
| 2019 | $196.0m (29.1%) | $-72.2m (10.1%) | $-89.5m (-65.2%) | -36.9% (30.3%) | $-0.50 (10.7%) |
| 2020 | $267.6m (36.5%) | $129.1m (278.7%) | $53.0m (159.2%) | 48.2% (230.9%) | $0.95 (290.0%) |
| 2021 | $443.3m (65.7%) | $402.7m (212.0%) | $298.0m (462.8%) | 90.8% (88.3%) | $2.86 (201.1%) |
| 2022 | $660.1m (48.9%) | $202.1m (-49.8%) | $235.3m (-21.0%) | 30.6% (-66.3%) | $1.48 (-48.3%) |
| 2023 | $829.3m (25.6%) | $281.6m (39.3%) | $373.3m (58.6%) | 34.0% (10.9%) | $2.13 (43.9%) |
| 2024 | $1.0b (22.4%) | $444.1m (57.7%) | $468.4m (25.5%) | 43.7% (28.8%) | $3.50 (64.3%) |
| 2025 | $1.4b (37.6%) | $316.9m (-28.6%) | $644.6m (37.6%) | 22.7% (-48.1%) | $2.64 (-24.6%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.